Implants News and Research

RSS

New knee replacement model increases likelihood of early revision surgery

Orthopaedic surgeons face a steep learning curve to get used to new prostheses, and the instruments and methods that go with them, before new total knee replacement procedures are as safe and effective as conventional methods. Patients who undergo the first 15 operations using a new device in a hospital are 48 percent more likely to need early revision surgery, than patients undergoing an operation to fit a prosthesis previously used in the hospital.

15 Dec 2011

Mazor Robotics to purchase Renaissance system for spine surgeries

Mazor Robotics Ltd., the leader in innovative surgical robots and complementary products for spine surgery, signed an agreement for the purchase of a Renaissance system with Richard R. M. Francis, MD, of Spine Associates of Houston and the Houston Orthopedic and Spine Hospital, formerly known as Foundation Surgical Hospital, in Bellaire, Texas.

12 Dec 2011

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced the initiation of two clinical studies for the nucleotide analogues ALS-2200 and ALS-2158, which are inhibitors of the hepatitis C NS5B polymerase.

12 Dec 2011

Abbott commences Absorb-XIENCE PRIME comparative clinical trial

Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME™ Everolimus Eluting Coronary Stent System.

9 Dec 2011

Breast reconstruction surgery to become safer and more realistic

Breast reconstruction surgery will become both safer and more realistic thanks to research led by Queensland University of Technology (QUT) in Brisbane, Australia.

7 Dec 2011

Xeltis receives PEI conditional approval to initiate tissue-engineered cardiovascular graft study

Xeltis, a biomedical technology company developing growing, living and self-healing cardiovascular implants using tissue-engineering technology, has announced conditional approval by the Paul Erlich Institute (PEI) in Germany to commence the first clinical study of its tissue-engineered cardiovascular grafts.

6 Dec 2011

MHI cardiologists use ABSORB bioresorbable vascular scaffold to treat CAD

The interventional cardiology team at the Montreal Heart Institute (MHI) used the world's first drug eluting bioresorbable vascular scaffold to successfully treat a woman suffering from coronary artery disease. This landmark procedure was performed by Dr. Jean-Fran-ois Tanguay, interventional cardiologist and coordinator of the Coronary Unit, as part of the ABSORB EXTEND clinical trial.

6 Dec 2011

MRG releases 2012 report on European markets for large-joint reconstructive implants

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European market for large-joint reconstructive implants will grow moderately through 2016.

5 Dec 2011

Study reveals no clear advantage of one implant type over another

More than 270,000 Americans get hip replacement surgeries every year -- a number that is projected to double in the next decade as the population ages. With various options for implants, including metal-on-polyethylene, metal-on-metal and ceramic-on-ceramic, there have been questions about which kind works best.

1 Dec 2011

Novel nanocarbon platform shows potential for future bioelectronic implants

Researchers have demonstrated, for the first time, a graphene-based transistor array that is compatible with living biological cells and capable of recording the electrical signals they generate.

1 Dec 2011

Nanosized metallic particles on implant surfaces may reduce risk of rejection

Coating the surface of an implant such as a new hip or pacemaker with nanosized metallic particles reduces the risk of rejection, and researchers at the University of Gothenburg, Sweden, can now explain why: they fool the innate immune system.

30 Nov 2011

Scientists use genetic methods to successfully repair cleft lips in mice embryos

Scientists at Weill Cornell Medical College used genetic methods to successfully repair cleft lips in mice embryos specially engineered for the study of cleft lip and cleft palate. The research breakthrough may show the way to prevent or treat the conditions in humans.

29 Nov 2011

IsoRay initiates shipment of GliaSite radiation therapy system

IsoRay, Inc. announced today it has shipped its first GliaSite radiation therapy system. The Company initiated sales after receiving final approval this week from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system.

28 Nov 2011

ArthroCare reaches agreement in principle to settle private securities class action suits

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced that it has reached an agreement in principle to settle the private securities class action suits pending against the Company and two of its former officers.

28 Nov 2011

Bacterin to distribute Jeil's LeForte craniomaxillofacial system in the U.S. and Canada

Bacterin International Holdings, Inc., a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, signed an exclusive agreement with Jeil Medical Corporation for distribution in the U.S. and Canada of Jeil's LeForte System.

28 Nov 2011

IsoRay receives Washington State approval for GliaSite system to treat brain cancer

IsoRay, Inc. announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay's final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States.

22 Nov 2011

Naltrexone for problem gamblers

According to new practice guidelines Australian doctors treating gambling addicts now can consider prescribing an anti-heroin drug, naltrexone, to help problem gamblers control their impulses. Australia has one of the world’s highest rates of problem gamblers, with about 2.1 per cent of Australians experiencing some form of gambling problem.

22 Nov 2011

FDA allows marketing of Aptus EndoStapling System to treat AAA

The U.S. Food and Drug Administration today allowed marketing of the first system that can repair a failed or problematic aortic endograft, a fabric tube used to repair a dangerously large aortic aneurysm, a bulge in the large blood vessel that carries blood away from the heart.

22 Nov 2011

Retina Implant scientific advisory board approves multi-center phase of second human clinical trial

Retina Implant AG, the leading developer of subretinal implants for retinitis pigmentosa patients, today announced that its scientific advisory board is in full support of beginning the multi-center phase of the Company's second human clinical trial. The trial, which began in Tuebingen, Germany in 2010, will be expanded across Europe in five new sites, including two additional locations in Germany, Oxford, London and Budapest.

21 Nov 2011

MedSolutions introduces ICD Surgery Management Program

MedSolutions, a leading provider of quality-driven medical cost management services, today announced the launch of its Implantable Cardioverter Defibrillator (ICD) Surgery Management Program, which uses evidence-based guidelines to ensure the clinical appropriateness of ICD and CRT-D implantation.

19 Nov 2011